Clinical Trial Update: An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). [Phase 1]

View source ↗

Summary

Phase 1 ascending-dose study of PIT565 in participants with systemic lupus erythematosus is currently recruiting to assess safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• PIT565 (PIT565)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Lupus Erythematosus, SLE | Phase 1 | Status: RECRUITING